Trial site
Diabetes Zentrum Wilhelmsburg GbR
Hamburg, 21109, GermanyNot linked to an institution yet
- 17running trials
- 4closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 319 trials
- Phase 42 trials
- Status
- Active, not recruiting8 trials
- Recruiting6 trials
- Completed4 trials
- Not yet recruiting3 trials
- Lead sponsor
- Eli Lilly and Company7 trials
- Novo Nordisk A/S6 trials
- AstraZeneca3 trials
- Boehringer Ingelheim2 trials
- Pfizer2 trials
- and 1 more
Running trials
Recruiting
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT07855900· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213· Phase 3· AstraZeneca· Source
Active, not recruiting
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· Phase 3· Pfizer· Source
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850· Phase 3· Pfizer· Source
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600· Phase 3· Eli Lilly and Company· Source
Recruiting
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
NCT07112339· Phase 4· Novo Nordisk A/S· Source
Active, not recruiting
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199· Phase 3· Novo Nordisk A/S· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895· Phase 3· Eli Lilly and Company· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
NCT03811561· Phase 3· Novo Nordisk A/S· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error